Plecanatide

Drug Profile

Plecanatide

Alternative Names: GCRA; Guanilib; SP-304; TRULANCE

Latest Information Update: 30 Jan 2017

Price : $50

At a glance

  • Originator Callisto Pharmaceuticals
  • Developer Synergy Pharmaceuticals Inc
  • Class Anti-inflammatories; Peptides
  • Mechanism of Action Guanylate cyclase C agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Constipation
  • Phase III Irritable bowel syndrome
  • Discontinued Inflammatory bowel diseases; Ulcerative colitis

Most Recent Events

  • 19 Jan 2017 Synergy Pharmaceuticals completes a phase III trial in Irritable bowel syndrome (characterised by constipation) in USA (PO) (NCT02493452)
  • 19 Jan 2017 Synergy Pharmaceuticals completes a phase III trial in Irritable bowel syndrome (Characterised by constipation) in USA (PO) (NCT02387359)
  • 19 Jan 2017 The approved US label for plecanatide carries a black box warning
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top